HC Wainwright Analysts Raise Earnings Estimates for MLYS

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) – Analysts at HC Wainwright upped their Q1 2026 earnings per share estimates for Mineralys Therapeutics in a report released on Monday, March 16th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings of ($0.44) per share for the quarter, up from their prior estimate of ($0.52). HC Wainwright has a “Buy” rating and a $56.00 price objective on the stock. The consensus estimate for Mineralys Therapeutics’ current full-year earnings is ($4.23) per share. HC Wainwright also issued estimates for Mineralys Therapeutics’ Q2 2026 earnings at ($0.50) EPS, Q3 2026 earnings at ($0.56) EPS, Q4 2026 earnings at ($0.63) EPS, FY2026 earnings at ($2.14) EPS, FY2027 earnings at ($2.40) EPS and FY2028 earnings at ($0.90) EPS.

Mineralys Therapeutics (NASDAQ:MLYS) last issued its earnings results on Thursday, March 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.17.

MLYS has been the topic of a number of other reports. Bank of America lifted their target price on shares of Mineralys Therapeutics from $46.00 to $51.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Thursday, January 22nd. Wall Street Zen upgraded shares of Mineralys Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, March 15th. Stifel Nicolaus lifted their price target on shares of Mineralys Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Finally, Jefferies Financial Group reiterated a “hold” rating and issued a $30.00 price objective on shares of Mineralys Therapeutics in a report on Friday, March 13th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $49.14.

Mineralys Therapeutics Trading Down 2.6%

Shares of MLYS stock opened at $23.28 on Wednesday. Mineralys Therapeutics has a twelve month low of $10.44 and a twelve month high of $47.65. The company’s 50-day moving average price is $29.61 and its 200-day moving average price is $35.62. The stock has a market cap of $1.92 billion, a price-to-earnings ratio of -9.82 and a beta of 0.57.

Insider Buying and Selling at Mineralys Therapeutics

In other Mineralys Therapeutics news, insider David Malcom Rodman sold 192,715 shares of Mineralys Therapeutics stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $35.02, for a total transaction of $6,748,879.30. Following the completion of the sale, the insider directly owned 61,804 shares in the company, valued at $2,164,376.08. This trade represents a 75.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Adam Scott Levy sold 10,758 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $32.14, for a total transaction of $345,762.12. Following the completion of the sale, the chief financial officer directly owned 8,638 shares in the company, valued at $277,625.32. This trade represents a 55.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 363,325 shares of company stock valued at $12,298,347 over the last 90 days. 25.56% of the stock is owned by insiders.

Hedge Funds Weigh In On Mineralys Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Smartleaf Asset Management LLC increased its holdings in Mineralys Therapeutics by 198.2% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company’s stock valued at $40,000 after purchasing an additional 676 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Mineralys Therapeutics by 4.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,085 shares of the company’s stock worth $271,000 after purchasing an additional 702 shares in the last quarter. Navalign LLC purchased a new position in shares of Mineralys Therapeutics during the fourth quarter worth $33,000. Velan Capital Investment Management LP boosted its position in shares of Mineralys Therapeutics by 0.6% during the third quarter. Velan Capital Investment Management LP now owns 175,600 shares of the company’s stock worth $6,659,000 after buying an additional 1,000 shares during the period. Finally, Royal Bank of Canada grew its stake in shares of Mineralys Therapeutics by 262.3% in the fourth quarter. Royal Bank of Canada now owns 1,529 shares of the company’s stock valued at $56,000 after buying an additional 1,107 shares in the last quarter. Hedge funds and other institutional investors own 84.46% of the company’s stock.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.